rs1554286

This prospective case-control study examined genetic variation in immune response genes and prostate cancer risk in the Prostate Cancer Prevention Trial (PCPT) placebo arm. Among 881 cases and 848 controls, the minor allele of rs3212227 in IL12(p40) was associated with increased prostate cancer risk (OR=1.30, 95% CI 1.10-1.53, P-trend=0.0017), particularly for lower-grade disease. The minor alleles of IL10 tagSNPs rs3021094 (OR=1.31, 95% CI 1.03-1.66, P-trend=0.03) and rs1800890 (OR=0.87, 95% CI 0.75-0.99, P-trend=0.04) showed significant associations. The study investigated whether observed associations were explained by PSA-associated detection bias and found that associations persisted in men with low PSA levels.

This is a Turkish master's thesis investigating the relationship between the rs924080 variant in the IL23R-IL12RB2 intergenic region (previously identified as Behçet's disease-associated in GWAS studies, P<0.0001) and IL23R/IL12RB2 gene expression in healthy volunteers. The study examined 14 healthy subjects (6 heterozygous AG, 4 homozygous AA, 4 GG control for the risk A allele) and found that the rs924080 A risk allele significantly enhanced IL-23R stimulation responses and IL-6 cytokine production, suggesting a modulatory role in Th17 and IL-6 responses implicated in Behçet's disease pathogenesis.

Nested case-control study of 258 prostate cancer cases and 258 matched controls in the CLUE II prospective cohort examining genetic variants in inflammation and obesity-related genes. The IL10 -1082G>A variant (rs1800896, A allele) was positively associated with prostate cancer risk (AG vs GG: OR=1.69, 95% CI 1.10-2.60; AA vs GG: OR=1.81, 95% CI 1.11-2.96), while a TLR4 variant (rs4986790) showed inverse association, and no consistent associations were found for obesity-related gene variants.